San Diego, CA, United States of America

Bi-Yu Li

This inventor holds 3 USPTO granted patents. Top assignee: Syngenta Participations Ag. Active years: 2004-2007.


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2004-2007

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Bi-Yu Li: Innovator in Genetic Marker Identification

Introduction

Bi-Yu Li is a prominent inventor based in San Diego, CA (US). He has made significant contributions to the field of genetics, particularly in the identification of genetic markers and nucleic acid fragments. With a total of 3 patents, his work has broad applications in various scientific domains.

Latest Patents

Bi-Yu Li's latest patents include a method for the identification of genetic markers. This method provides innovative techniques for determining methylation patterns using restriction endonucleases with degenerate recognition or cleavage sequences. Another notable patent is for the identification, separation, and quantitative measurement of nucleic acid fragments. This invention utilizes restriction endonucleases that have degenerate bases in their recognition or cleavage sequence, offering applications in DNA fingerprinting, differential display of mRNA, mutation and polymorphism identification, diagnosis, and drug screening.

Career Highlights

Bi-Yu Li is currently associated with Syngenta Participations AG, where he continues to advance his research and innovations. His work has positioned him as a key figure in the field of genetic research.

Collaborations

Some of his notable coworkers include Xun Wang and Liang Shi, who have collaborated with him on various projects.

Conclusion

Bi-Yu Li's contributions to genetic research through his innovative patents highlight his role as a leading inventor in the field. His work continues to impact the scientific community and advance our understanding of genetics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…